Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
USFRKT
1 other identifier
observational
94,017
2 countries
2
Brief Summary
Despite the considerable advances in short-term outcomes, kidney transplant recipients continue to suffer from late allograft failure, and little improvement has been made over the past 15 years. The worldwide scarcity of donated kidneys and the decline in the number of living donor transplants have prompted a variety of efforts to expand the organ supply, such as accepting organs from donors who were older or had comorbidities or other injuries. Two major initiatives from the United Network for Organ Sharing (UNOS), the organization responsible for organ allocation in the US, failed to improve the kidney acceptance rate. First, UNOS introduced the Kidney Donor Risk Index (KDRI) for all kidney offers in 2012. The KDRI is a score that predicts survival of deceased donor kidneys based on 10 donor characteristics and was intended to simplify the process of judging organ quality for clinicians. Second, in 2014, UNOS changed the kidney allocation system so that lower-quality kidneys are offered over wider geographic areas. Despite the ongoing severe organ shortage and these allocation initiatives, the number of discarded kidneys rose from 2,127 (14.9%) in 2006 to 3,631 (20%) in 2016. In this context, the experience of transplant programs outside the US could offer novel approaches to making organ utilization more efficient through the examination of the disposition of organs that are usually discarded in the US. This project aims:
- 1.To evaluate the potential benefit of transplanting kidneys that would have been discarded otherwise in the US
- 2.Computer simulation models on real life data to estimate the number of kidney transplants that would have taken place using data from a nationwide cohort study in two countries (France, the US);
- 3.To evaluate the potential gains in allograft survival years that would result in the US from a less restrictive kidney acceptance practice such as the one from France.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2017
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 9, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2018
CompletedFirst Submitted
Initial submission to the registry
October 24, 2018
CompletedFirst Posted
Study publicly available on registry
October 29, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 29, 2020
CompletedMay 1, 2020
April 1, 2020
1 year
October 24, 2018
April 29, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of kidneys procured and discarded.
In some instances, the two kidneys might be procured from one donor but one or both kidneys may eventually be discarded and thus, not transplanted. This information was retrieved in both the OPTN data system and CRISTAL registry.
10 years
Secondary Outcomes (1)
Probability of allograft failure after transplantation.
10 years
Study Arms (2)
OPTN data system
In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
CRISTAL registry
In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
Eligibility Criteria
All kidney transplantation occurring in France and in the US from 2004 to 2014 with available data to calculate the KDRI and the Kidney Donor Profile Index (KDPI), with lower values suggestive of better quality. The KDRI and KDPI are currently used as part of the OPTN allocation system for deceased donor kidneys in the US and have been validated as reliable measures of organ quality in the US.
You may qualify if:
- All consecutive kidneys recovered for the purpose of transplantation from donors deceased from brain death or circulatory death,
- Between January 1, 2004 and December 31, 2014.
You may not qualify if:
- Living renal transplants,
- Multiorgan transplant recipients,
- Kidneys offered to transplant centers but never recovered, and
- Patients with missing data to calculate the KDRI score
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Paris Translational Research Center for Organ Transplantationlead
- University of Pennsylvaniacollaborator
- Agence de La Biomédecinecollaborator
Study Sites (2)
Kidney Transplantation Care at Veteran's Affairs Medical Center
Philadelphia, Pennsylvania, 19104, United States
Paris Transplant Group
Paris, 75015, France
Related Publications (1)
Aubert O, Reese PP, Audry B, Bouatou Y, Raynaud M, Viglietti D, Legendre C, Glotz D, Empana JP, Jouven X, Lefaucheur C, Jacquelinet C, Loupy A. Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. JAMA Intern Med. 2019 Oct 1;179(10):1365-1374. doi: 10.1001/jamainternmed.2019.2322.
PMID: 31449299DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Reese, MD
Kidney Transplantation Care at Veteran's Affairs Medical Center
- PRINCIPAL INVESTIGATOR
Alex Loupy
Paris Transplant Group, INSERM, UMR-S970, Paris, France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 24, 2018
First Posted
October 29, 2018
Study Start
October 9, 2017
Primary Completion
October 11, 2018
Study Completion
March 29, 2020
Last Updated
May 1, 2020
Record last verified: 2020-04